2025 Business Predictions: Sam Berry, Managing Director of the Berry Group
Boots sees strong first quarter
Rolls-Royce appoints design partners for Derby site expansion
Rolls-Royce Submarines Infrastructure Director Terry Meighan said: “The expansion work we have planned is of critical national importance as it enables us to safely increase our speed of manufacture, helping to deliver Dreadnought and the new SSN-AUKUS attack submarines at a much faster rate.
Andy Smart, Head of Major Projects – Nuclear, AtkinsRéalis, said: “These new facilities will be vital to deliver new submarines safely, swiftly and efficiently and we’re delighted to be appointed alongside Mott MacDonald to progress these plans at pace.
Jeremy Reed, Global Practice Leader – Nuclear, Mott MacDonald, said: “Mott MacDonald brings over 60 years of experience delivering complex technical solutions in highly regulated, secure, and safety-critical nuclear environments.
“Combined with our commitment to excellence, safety, and sustainability, this experience, along with that of our partner AtkinsRéalis, will play a key role in supporting Rolls-Royce Submarines to deliver the successful expansion of the Derby site, continuing our longstanding commitment to support the UK submarine enterprise.”
Shorts’ Managing Partner takes seat on global board
Housing provider launches tree replacement programme
East Midlands entrepreneurs hold back as local start-ups plummet
Peak District National Park Authority shares significant restructure proposals under financial pressures
Rolls-Royce signs engine agreement with STARLUX Airlines
Planning approval secured for new Public Mortuary in Northampton
Construction commences on over 100,000 sq ft of industrial premises and employee facilities at Silverstone Park
The Nottinghamshire Golf and Country Club acquired by UK’s largest country club operator
West Northamptonshire Council to pursue South Midlands devolution bid
Derbyshire biotech company makes key appointment
Derbyshire biotech company N4 Pharma has appointed Dr Alastair Smith as an independent Non-Executive Director.
Alastair was the founder and former Chief Executive Officer of Avacta Group, an AIM-listed biotech company established as a spin-out from Leeds University in 2005 and listed on the London Stock Exchange AIM market in 2006.
Over his tenure, Avacta grew into one of the leading AIM biotech companies comprising two divisions: a clinical stage oncology drug company and a diagnostics business.
Alastair joins the company’s remuneration and audit committees.
Nigel Theobald, Chief Executive Officer, N4 Pharma, said: “We are delighted to welcome Alastair to the Board of N4 Pharma. His experience in having founded and grown a start-up to become one of the UK’s leading life science businesses will be invaluable in supporting the commercialisation of Nuvec® and advancing our pipeline of innovative therapies.”
The news comes as David Templeton retires as a Director of the company.Nigel added: “On behalf of my fellow Directors and everyone involved with N4 Pharma, I would like to thank David for all he has contributed over his years with the Company. Whilst he will be sorely missed, his work on dual loading of Nuvec® and its potential for oral delivery has left us with a true point of difference and a clear path towards Phase 1 clinical trials. We wish him all the best for the future.”
Alastair Smith said: “I am delighted to be joining the Board of N4 Pharma. I see strong parallels between N4 Pharma and Avacta; both building a pipeline of therapies that are strongly differentiated by a proprietary platform technology and offer additional opportunities for early commercialisation through licensing.”